Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 49.23 -4.92% -2.55
PTLA closed down 4.92 percent on Tuesday, December 12, 2017, on 1.54 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Dec 12 Fell Below 50 DMA Bearish 0.00%
Dec 12 200 DMA Support Bullish 0.00%
Dec 12 Multiple of Ten Bearish Other 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Oversold Stochastic Weakness 0.00%
Dec 11 Bearish Engulfing Bearish -4.92%
Dec 11 Outside Day Range Expansion -4.92%
Dec 11 Wide Bands Range Expansion -4.92%
Dec 8 NR7 Range Contraction -7.15%
Dec 8 Wide Bands Range Expansion -7.15%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.1
52 Week Low 17.74
Average Volume 678,509
200-Day Moving Average 48.51
50-Day Moving Average 50.6662
20-Day Moving Average 50.461
10-Day Moving Average 51.438
Average True Range 2.2332
ADX 15.66
+DI 23.54
-DI 27.44
Chandelier Exit (Long, 3 ATRs ) 48.6904
Chandelier Exit (Short, 3 ATRs ) 53.1996
Upper Bollinger Band 53.8174
Lower Bollinger Band 47.1046
Percent B (%b) 0.32
BandWidth 13.302947
MACD Line 0.3337
MACD Signal Line 0.245
MACD Histogram 0.0887
Fundamentals Value
Market Cap 2.84 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -10.82
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.39
Resistance 3 (R3) 54.72 53.33 53.53
Resistance 2 (R2) 53.33 52.02 53.17 53.24
Resistance 1 (R1) 51.28 51.20 50.59 50.95 52.96
Pivot Point 49.89 49.89 49.54 49.73 49.89
Support 1 (S1) 47.84 48.58 47.15 47.51 45.50
Support 2 (S2) 46.45 47.76 46.29 45.22
Support 3 (S3) 44.40 46.45 44.93
Support 4 (S4) 44.07